Powered By
The American Academy of Neurology is in the midst of their Annual Meeting (April 5 - 9, 2025) and this was presented yesterday:
https://www.medpagetoday.com/meetingcoverage/aa...
@A myALZteam Member @A myALZteam Member Thank you! I have printed this out & will share with my family. It's great to have some good news to share with all!
Interesting. I am awaiting permission to start one of the 2 approved drugs!
@A myALZteam Member Please see news about Lecanemab in @A myALZteam Member 's Post today, it's a question in the Q&A section with title: "Alzheimer's Lecanemab Treatment Up To 36 Months Supported By Extension Study" I hope this is good news for you. I remember you had asked for any current news about the trial. I also flag this to @A myALZteam Member and @A myALZteam Member
ADDED snippets after reading through the conference report referenced by Helen:
1. "They also suggest that individuals with lower pathology -- no or low tau, or low amyloid -- experience a particularly robust stabilization of symptoms," he continued. "These results collectively underscore the importance of early initiation and continued long-term treatment."
2. No new safety signals were observed with continued lecanemab treatment. After the first 6 months, ARIA rates were similar to rates seen with placebo, van Dyck and colleagues reported.
3. "The evidence that patients who are very mild at entry into lecanemab treatment can stabilize and even improve to some extent is highly encouraging and supports the conclusion that lecanemab is truly a disease-modifying medicine for Alzheimer's disease," Selkoe told MedPage Today.
"The data encourage neurologists to begin mild cognitive impairment and mild Alzheimer's patients on lecanemab when they are early in their symptomatic phase and continue the treatment, if they tolerate it, for as long as 3 years -- possibly at half the usual dose frequency -- or longer, depending on further observations," he added.
The extension study did not discuss when lecanemab treatment should end. "I don't think we have any definitive evidence about when to discontinue treatment," van Dyck said. "In my experience, in the clinic, that is a decision that physicians are making case-by-case with their patients and families."
Please read the whole paper if you are interested and don't hesitate to start further discussions.
Thanks for posting this. It’s good news.
I have a neighbor who is in this. Unfortunately my husband is no longer in mild stage
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
